CTRI/2022/02/040674已完成未知
A prospective, blinded, randomized active-controlled clinical trial to evaluate the success of double antibiotic paste in pulpally infected primary molars
Dr Urvashi Sharma0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.signs of severe pain
- •2.pathologic tooth mobility
- •3.abscess or sinus formation
- •4.pathologic root resorption
- •5.radiolucency in the furcation area
- •6.Restorable tooth
排除标准
- •1.known sensitivity or allergy to drugs
- •2.systemic conditions
- •3.extensive root resorption
- •4.perforated pulpal floor
- •5.unrestorable tooth
研究者
相似试验
进行中（未招募）
1 期
Effect on secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (adalimumab biosimilar)EUCTR2017-000679-10-PLovartis Pharma AG837
进行中（未招募）
1 期
Effect on secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (adalimumab biosimilar)Ankylosing spondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2017-000679-10-PTovartis Pharma AG859
进行中（未招募）
1 期
Effect on secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (adalimumab biosimilar)Ankylosing spondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2017-000679-10-ESovartis Farmacéutica, S.A.837
进行中（未招募）
1 期
A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis - SURPASSAnkylosing spondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2017-000679-10-GRovartis Pharma AG837
进行中（未招募）
1 期
A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis - SURPASSEUCTR2017-000679-10-FRovartis Pharma AG837